Nancy Freda-Smith
Director at Tempest Therapeutics.
- Brisbane, CA
- Tempest Therapeutics
Raised on Tempest Therapeutics filings
$13.6M
of $13.6M offered across 3 Form D filings
- Form D filings
- 3
- Teammates
- 11
- Last filing
- Oct 13, 2026
Company
In vivo CAR-T therapies for autoimmune disease and cancer
- Investors
- 3
Tempest Therapeutics filings
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Oct 13, 2026 | Security to be acquired | $7.5M/ $7.5M | Form D |
| Jun 23, 2026 | Equity | $4.1M/ $4.1M | Form D |
| Apr 3, 2026 | Equity | $2M/ $2M | Form D |
Works with
Matthew AngelPresident and Chief Executive Officer, Form D signerForm D signerStephen BradyDirectorWilliam RicheyDirectorJohn FrederickDirectorJustin TrojanowskiVice President, Finance, Principal Financial Officer and Corporate SecretaryJohn David YeeDirectorConstance AmesChief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate SecretaryChristine PellizzariDirectorMichael RaabDirectorNicholas MaestasExecutive OfficerRonit SimantovDirector
